Bibliografia
- 1 - Mandal A, Mayberry J. (2003). Frequently asked questions about inflammatory bowel disease. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp743755). Edinburgh: Churchill Livingstone Elsevier.
- 2 - Travis S, Jewel DP. (2003). Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp169181). Edinburgh: Churchill Livingstone Elsevier.
- 3 - Pallone F, Monteleone G, Montelone I, Biancone L. (2003). The immune system in inflammatory bowel disease. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp8593). Edinburgh: Churchill Livingstone Elsevier.
- 4 - Panès J Sans M, Piquè JM. (2003). Cell adhesion molecules. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp121131). Edinburgh: Churchill Livingstone Elsevier.
- 5 - Marshall JK, Hilsden RJ. (2003). Environment and epidemiology of inflammatory bowel disease. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp1728). Edinburgh: Churchill Livingstone Elsevier.
- 6 - Trallori G, Palli D, Saieva C, et al. A population-based study of inflammatory bowel disease in Florence over 15 years (197892). Scand J Gastroenterol 1996;31:8929.
- 7 - Manuale di Gastroenterologia UNIGASTRO Edizione 2004-2006 pagg 439-440
- 8 - Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28(2):25581, vii.
- 9 - Orchard TR. (2003). Extraintestinal manifestations: skin, joints and mucocutaneous manifestations. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp669684). Edinburgh: Churchill Livingstone Elsevier.
- 10 - Satsangi J. (2003). Chapter 6. Overview. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp585587). Edinburgh: Churchill Livingstone Elsevier.
- 11 - Ullman TA, Itzkowitz SH. (2003). Cancer risk in inflammatory bowel disease. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp605619). Edinburgh: Churchill Livingstone Elsevier.
- 12 - Dott. Paolo Gionchetti, IBD Research Hospital, University of Bologna, www.amiciitalia.org. Accessed 23 March 2009.
- 13 - Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107(1):311.
- 14 - Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2008 Nov 4. [Epub ahead of print].
- 15 - Crohn's and Colitis Foundation of America. Treatment options in IBD. http://www.ccfa.org/info/treatment/ Accessed 23 March 2009.
- 16 - Panaccione R, Fedorak RN. Primer of current therapies to treat inflammatory bowel disease. In: Satsangi J, Sutherland LR (Eds.), Inflammatory Bowel Diseases (pp335358). Edinburgh: Churchill Livingstone Elsevier.
- 17 - Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):246276.


